EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Exploring the Clinical Value of Perioperative ctDNA ‐Based Detection of Molecular Residual Disease in Patients With Esophageal Squamous Cell Carcinoma

Jimin Li iD, Congcong Wu, Yongming Song, Yuhui Fan, Chao Li, Haibo Li, Shuangping Zhang iD

Thoracic Cancer · 2025-02 · 16 (4)

DOI: 10.1111/1759-7714.70017 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Thoracic Cancer, online erschienen am 18.02.2025. Verfasst von Jimin Li und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Thoracic Surgery, Cancer Hospital Affiliated to Shanxi Medical University, Shanxi Province Cancer Hospital, Shanxi Hospital Affiliated …. Hauptthemen laut MEDLINE: Circulating Tumor DNA, Esophageal Squamous Cell Carcinoma, Neoplasm, Residual, Esophageal Neoplasms. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Science Fundation of Shanxi Health Commission, The Science and Education Cultivation Fund of the National Cancer and Regional Medical Center of Shanxi Provincial Cancer Hospital, Supported by Fundamental Research Program of Shanxi Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

To explore the clinical value of molecular residual disease detection based on circulating tumor DNA (ctDNA‐MRD) in the perioperative period of esophageal squamous cell carcinoma (ESCC) and to analyze the tumor escape mechanisms in MRD‐positive cases.

Methods

A total of 35 ESCC patients were prospectively enrolled. Preoperative and postoperative (1 month after surgery) blood and surgical tissue samples were analyzed. ctDNA variants were tracked in plasma to assess ctDNA‐MRD, and whole‐transcriptome sequencing was performed on MRD‐positive and MRD‐negative tissue samples.

Results

Preoperative blood ctDNA was positive in 54.3% of patients, with a 31.6% positive predictive value for recurrence. One month postsurgery, the positive rate of ctDNA was 17.1%, with an 83.3% predictive value for recurrence. Both preoperative and postoperative ctDNA positivity were significant prognostic indicators (HR = 2.78, p < 0.05; HR = 4.42, p < 0.001). Multivariate analysis confirmed ctDNA as an independent prognostic factor (HR = 303.75, p < 0.001). Transcriptomic analysis revealed increased macrophage (W = 15 848; p < 0.01) and follicular helper T (Tfh) cell (W = 10 935; p < 0.01) levels in MRD‐positive patients, suggesting a potential link to immune escape in tumors.

Conclusions

Plasma ctDNA measured 1 month postoperatively in ESCC patients can effectively detect MRD, and ctDNA‐MRD serves as an independent risk factor for postoperative recurrence. The mechanism underlying MRD positivity may involve the polarization of Tfh cells and macrophages, aiding tumor cells in immune escape through the bloodstream.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Circulating Tumor DNAEsophageal Squamous Cell CarcinomaNeoplasm, ResidualEsophageal NeoplasmsBiomarkers, TumorHumansMaleFemaleMiddle AgedPrognosisAgedProspective StudiesPerioperative PeriodNeoplasm Recurrence, Local

Stichwörter der Autor:innen

ESCCctDNAmolecular residual disease

Substanzen

Circulating Tumor DNABiomarkers, Tumor

Autor:innen und Institutionen

  • Department of Thoracic Surgery, Cancer Hospital Affiliated to Shanxi Medical University, Shanxi Province Cancer Hospital, Shanxi Hospital Affiliated to Cancer Hospital, Chinese Academy of Medical Sciences, Taiyuan, Chin…
  • Department of Thoracic Surgery, Shanxi Province Cancer Hospital, Shanxi Hospital Affiliated to Cancer Hospital, Chinese Academy of Medical Sciences, Cancer Hospital Affiliated to Shanxi Medical University, Taiyuan, Chin…
  • Department of Thoracic Surgery, Jincheng Second People's Hospital, Jincheng, China.
  • Department of Thoracic Surgery, Yuncheng Central Hospital, Yuncheng, China.

ORCID-Profile: Jimin Li, Shuangping Zhang

Förderung

  • Science Fundation of Shanxi Health Commission
  • The Science and Education Cultivation Fund of the National Cancer and Regional Medical Center of Shanxi Provincial Cancer Hospital
  • Supported by Fundamental Research Program of Shanxi Province
  • Research Project Supported by Shanxi Scholarship Council of Chin

Zitieren

APA

Li, J., Wu, C., Song, Y., Fan, Y., Li, C., Li, H., & Zhang, S. (2025). Exploring the Clinical Value of Perioperative ctDNA ‐Based Detection of Molecular Residual Disease in Patients With Esophageal Squamous Cell Carcinoma. Thoracic Cancer, 16(4). https://doi.org/10.1111/1759-7714.70017

Vancouver

Li J, Wu C, Song Y, Fan Y, Li C, Li H, et al. Exploring the Clinical Value of Perioperative ctDNA ‐Based Detection of Molecular Residual Disease in Patients With Esophageal Squamous Cell Carcinoma. Thoracic Cancer. 2025;16(4). doi:10.1111/1759-7714.70017

BibTeX
@article{Li2025,
  author = {Li, Jimin and Wu, Congcong and Song, Yongming and Fan, Yuhui and Li, Chao and Li, Haibo and Zhang, Shuangping},
  title = {Exploring the Clinical Value of Perioperative ctDNA ‐Based Detection of Molecular Residual Disease in Patients With Esophageal Squamous Cell Carcinoma},
  journal = {Thoracic Cancer},
  year = {2025},
  volume = {16},
  number = {4},
  doi = {10.1111/1759-7714.70017}
}
Kostenlos starten →